Keros Therapeutics (KROS) Interest Coverage Ratio (2019 - 2022)
Keros Therapeutics posted quarterly Interest Coverage Ratio of 24126.0 for Q1 2022, down 53.0% year-on-year from 51327.97 in Q1 2021, and down 395.81% on a QoQ basis from 4866.0 in Q4 2021.
Keros Therapeutics (KROS) has 4 years of Interest Coverage Ratio data on file, last reported at 24126.0 in Q1 2022.
- For the quarter ending Q1 2022, Interest Coverage Ratio fell 53.0% year-over-year to 24126.0; the trailing twelve-month figure through Dec 2022 stood at 114790.0 (down 714.5% YoY), and the FY2022 full-year result was 114790.0, down 714.5% from the prior year.
- Interest Coverage Ratio for Q1 2022 stood at 24126.0, down from 4866.0 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 775.33 in Q3 2019 and bottomed at 24126.0 in Q1 2022.
- The 4-year median for Interest Coverage Ratio is 8444.0 (2020), against an average of 9954.99.
- The widest annual swing landed in 2020, when Interest Coverage Ratio slumped 723.39%; it then surged 63.39% in 2021.
- A 4-year view of Interest Coverage Ratio shows it stood at 775.33 in 2019, then sank by 1614.23% to 13291.0 in 2020, then soared by 63.39% to 4866.0 in 2021, then tumbled by 395.81% to 24126.0 in 2022.
- The last three Interest Coverage Ratio figures came in at 24126.0 (Q1 2022), 4866.0 (Q4 2021), and 20197.0 (Q3 2021), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -24,126.00 |
| Dec 31, 2021 | -4,866.00 |
| Sep 30, 2021 | -20,197.00 |
| Jun 30, 2021 | -15,541.00 |
| Mar 31, 2021 | -15,769.00 |
| Dec 31, 2020 | -13,291.00 |
| Sep 30, 2020 | -5,974.00 |
| Jun 30, 2020 | -10,914.00 |
| Mar 31, 2020 | -5,252.00 |
| Sep 30, 2019 | -775.33 |
| Jun 30, 2019 | -1,325.50 |
| Mar 31, 2019 | -1,429.00 |